Board Meeting

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1131.1529.1 (+2.64 %)
PREV CLOSE ( ) 1102.05
OPEN PRICE ( ) 1111.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 93408
TODAY'S LOW / HIGH ( )1104.00 1137.15
52 WK LOW / HIGH ( )581.5 1177
NSE1131.3027.9 (+2.53 %)
PREV CLOSE( ) 1103.40
OPEN PRICE ( ) 1109.00
BID PRICE (QTY) 1131.30 (1083)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1511617
TODAY'S LOW / HIGH( ) 1104.00 1137.50
52 WK LOW / HIGH ( )581.25 1177.1

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.